Pfizer (PFE)
26.21
-0.10 (-0.38%)
Pfizer is a global biopharmaceutical company that develops and manufactures innovative medicines and vaccines to improve health outcomes for people around the world
Renowned for its extensive research and development efforts, Pfizer focuses on various therapeutic areas including vaccines, oncology, immunology, cardiology, endocrinology, and rare diseases. The company is committed to addressing significant health challenges through the discovery of new treatments, leveraging cutting-edge science and technology. Pfizer also emphasizes partnerships and collaborations to expand its capabilities and enhance access to healthcare solutions.
Previous Close | 26.31 |
---|---|
Open | 26.33 |
Bid | 26.21 |
Ask | 26.23 |
Day's Range | 26.08 - 26.50 |
52 Week Range | 24.48 - 31.54 |
Volume | 42,502,514 |
Market Cap | 146.95B |
PE Ratio (TTM) | 18.59 |
EPS (TTM) | 1.4 |
Dividend & Yield | 1.680 (6.41%) |
1 Month Average Volume | 41,828,358 |
News & Press Releases
Curious about the most active S&P500 stocks in today's session? Get insights into the stocks that are leading the way in terms of trading volume and market attention.
Via Chartmill · March 19, 2025
Pfizer has completed its exit from Haleon, selling its entire stake for $3.1 billion. BlackRock's unit is now Haleon's largest shareholder with over 5%.
Via Benzinga · March 19, 2025
HHS is considering major cuts to federal HIV prevention funding as part of a CDC reorganization, potentially affecting programs like PrEP. Experts warn the move could hinder efforts to combat the epidemic.
Via Benzinga · March 19, 2025
Pfizer Inc. (NYSE: PFE) invites investors and the general public to view and listen to a webcast of a conference call with investment analysts at 10:00 a.m. EDT on Tuesday, April 29, 2025. The purpose of the call is to provide an update on Pfizer’s results, as reflected in the company’s First Quarter 2025 Performance Report, to be issued that morning.
By Pfizer Inc. · Via Business Wire · March 18, 2025
Protalix saw record revenue growth in 2024, driven by increased sales to Chiesi, Pfizer, and Brazil. The company aims to start a Phase 2 trial for PRX-115 in 2025.
Via Benzinga · March 17, 2025
Value investing has created more billionaires than any other strategy, like Warren Buffett, who built his fortune by purchasing wonderful businesses at reasonable prices.
But these hidden gems are few and far between - many stocks that appear cheap often stay that way because they face structural issues.
Via StockStory · March 17, 2025
As the craze of earnings season draws to a close, here’s a look back at some of the most exciting (and some less so) results from Q4. Today, we are looking at branded pharmaceuticals stocks, starting with Supernus Pharmaceuticals (NASDAQ:SUPN).
Via StockStory · March 14, 2025
Senators question Pfizer's partnership with UpScriptHealth, citing potential anti-kickback concerns and risks of increased costs in federal health programs.
Via Benzinga · March 13, 2025
Via The Motley Fool · March 13, 2025
ViiV Healthcare's EMBRACE study shows VH109 with CAB LA effectively suppresses HIV. The company also reports promising early data on VH184 and VH499 therapies.
Via Benzinga · March 12, 2025
Blue-chip stocks are established, financially strong, and consistently profitable publicly traded companies.
Via Talk Markets · March 12, 2025

The companies are looking to use protein degradation to take on some forms of breast cancer.
Via Investor's Business Daily · March 11, 2025

For the current year, BioNTech projected revenue of 1.7 billion euros to 2.2 billion euros, below the market consensus of 2.54 billion euros and a fall from last year's 2.75 billion euros.
Via Stocktwits · March 10, 2025

Arvinas and Pfizer's Phase 3 trial shows vepdegestrant significantly improves progression-free survival in breast cancer patients.
Via Benzinga · March 11, 2025

BioNTech SE exceeded earnings expectations with strong oncology pipeline development, despite reduced vaccine revenue.
Via The Motley Fool · March 10, 2025

– VERITAC-2 achieved its primary endpoint in the estrogen receptor 1-mutant population, demonstrating statistically significant and clinically meaningful improvement in progression-free survival –
By Arvinas Inc. · Via GlobeNewswire · March 11, 2025

Over the past six months, Pfizer’s shares (currently trading at $26.70) have posted a disappointing 10.2% loss, well below the S&P 500’s 3.8% gain. This might have investors contemplating their next move.
Via StockStory · March 10, 2025

Sen. Elizabeth Warren and other lawmakers raised concerns about Robert F. Kennedy Jr.'s private dinners with pharmaceutical executives at Mar-a-Lago, questioning his commitment to reducing corporate influence as Secretary of Health and Human Services.
Via Benzinga · March 10, 2025

BioNTech's Q4 revenue beat estimates despite lower COVID-19 vaccine sales. The company advances oncology programs, with key data updates expected in 2025.
Via Benzinga · March 10, 2025